Larry K Kvols

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi request reprint Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
    Larry K Kvols
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Endocr Relat Cancer 19:657-66. 2012
  2. pmc External beam irradiation of myocardial carcinoid metastases: a case report
    Jonathan Strosberg
    H, Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Med Case Reports 1:95. 2007
  3. pmc Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston MA, USA
    J Hematol Oncol 4:29. 2011
  4. ncbi request reprint Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver
    Larry K Kvols
    Neuroendocrine Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 7:765-72. 2009
  5. ncbi request reprint Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas
    Evita B Henderson-Jackson
    Department of Pathology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Anticancer Res 31:2957-62. 2011
  6. doi request reprint Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
  7. doi request reprint Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012
  8. doi request reprint Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels
    Aejaz Nasir
    Department of Interdisciplinary Oncology, Neuroendocrine Cancer Research Group, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Pancreas 36:309-13. 2008
  9. ncbi request reprint Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors
    Jonathan R Strosberg
    Hematology Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:72-8. 2006
  10. ncbi request reprint A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:127-37. 2011

Detail Information

Publications22

  1. doi request reprint Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
    Larry K Kvols
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Endocr Relat Cancer 19:657-66. 2012
    ..Pasireotide 600-900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy...
  2. pmc External beam irradiation of myocardial carcinoid metastases: a case report
    Jonathan Strosberg
    H, Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Med Case Reports 1:95. 2007
    ..To our knowledge, this is the first reported case of metastatic cardiac carcinoid treated with external beam irradiation...
  3. pmc Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston MA, USA
    J Hematol Oncol 4:29. 2011
    ....
  4. ncbi request reprint Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver
    Larry K Kvols
    Neuroendocrine Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 7:765-72. 2009
    ..In this article, the authors examine important techniques in the armamentarium of the interventional radiologist...
  5. ncbi request reprint Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas
    Evita B Henderson-Jackson
    Department of Pathology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Anticancer Res 31:2957-62. 2011
    ..Palladin is a metastasis-associated gene regulating cell motility. The expression of palladin protein in pancreatic neuroendocrine tumors (PET) and carcinomas (PECA) is not known...
  6. doi request reprint Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
    ..This classification has not been validated in a population consisting solely of midgut NETs. The purpose of this study was to test the prognostic validity of the classification in such a population...
  7. doi request reprint Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012
    ....
  8. doi request reprint Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels
    Aejaz Nasir
    Department of Interdisciplinary Oncology, Neuroendocrine Cancer Research Group, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Pancreas 36:309-13. 2008
    ..In summary, this is a unique case of metastatic VIP- and calcitonin-secreting pancreatic ECA with dramatic sustained clinical, biochemical, and objective tumor response to peptide receptor radionuclide therapy...
  9. ncbi request reprint Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors
    Jonathan R Strosberg
    Hematology Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:72-8. 2006
    ..Several reviews have suggested that hepatic artery embolization, with or without intraarterial chemotherapy, can be used for control of symptoms and for cytoreduction in patients with liver dominant metastases...
  10. ncbi request reprint A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:127-37. 2011
    ..New evidence demonstrates that these agents can also inhibit tumor growth. Other novel agents targeting the VEGF and mTOR pathways have recently been investigated in multicenter phase III studies...
  11. doi request reprint Revisiting C.G. Moertel's land of small tumors
    Larry K Kvols
    Moffitt Cancer Center, Tampa, FL, USA
    J Clin Oncol 26:5005-7. 2008
  12. ncbi request reprint Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors
    Dana A Osborne
    Digestive Disorders Center, Tampa General Hospital, 1 Davis Island, Tampa, Florida 33601, USA
    Ann Surg Oncol 13:572-81. 2006
    ..The purpose of this study was to determine whether cytoreduction provides any benefit over embolic management of diffuse neuroendocrine tumors...
  13. ncbi request reprint A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 16:219-24. 2007
    ..This review summarises the present scope of clinical research in this field...
  14. ncbi request reprint Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution
    James F Helm
    Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:288-94. 2008
    ....
  15. doi request reprint Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors
    Jonathan R Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, USA
    J Clin Oncol 29:3044-9. 2011
    ..This classification has not yet been validated...
  16. doi request reprint RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms
    Aejaz Nasir
    Department of Pathology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Pancreas 40:627-33. 2011
    ....
  17. ncbi request reprint Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
    Pamela J Hodul
    Gastrointestinal Tumor Program, Departmentsof Surgery, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:314-21. 2008
    ..This paper discusses whether aggressive surgical intervention is indicated for PNETs and investigates what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention...
  18. pmc Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Can J Gastroenterol 21:113-5. 2007
    ..To the authors' knowledge, this is the first case presentation of chronic, partial small bowel obstruction caused by unrecognized retention of a capsule endoscope...
  19. ncbi request reprint Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility
    Aejaz Nasir
    Gastrointestinal Tumor Program, Neuroendocrine Cancer Research, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:52-60. 2006
    ..In patients with SSTR-negative ETs, the clinical response is generally absent or suboptimal, while nonfunctioning ETs with SSTR positivity show a variable response to such therapy...
  20. ncbi request reprint Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors
    Larry K Kvols
    Inter Disciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Anticancer Drugs 17:601-8. 2006
    ....
  21. pmc The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Pancreas 39:799-800. 2010
    ..In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases...
  22. ncbi request reprint Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets
    Larry K Kvols
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33615, USA
    J Nucl Med 46:187S-90S. 2005
    ..This is an exciting time in clinical oncology research, because we have a plethora of new molecules to evaluate...